Evicenter
P&T meetings

Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted April 2026
Last updated
76 sources

Executive summary

Burden of Gastrointestinal stromal tumor

1 evidence topic · 3 sources

Summary

The cited U.S. epidemiology study reported an increase in annual age-adjusted incidence from 0.55 per 100,000 in 2001 to 0.78 per 100,000 in 2011. Severe fatigue occurred in 30% of participants with GIST and 33% of those receiving a TKI in the cited fatigue study. A recurrence-cost study reported an additional $4464 per patient per month in total healthcare costs for patients with recurrence.